Immuron (IMRN) Interest & Investment Income (2017 - 2024)
Immuron (IMRN) recorded quarterly Interest & Investment Income of $35.3 billion in Q4 2024, up 3533301692.76% quarter-over-quarter from $999.32 in Q4 2023, and up 3533301692.76% on a YoY basis from N/an in Q1 2024.
Immuron (IMRN) Interest & Investment Income (2017 - 2024) Analysis & Trends
Immuron's Interest & Investment Income history runs 8 years deep, the most recent figure standing at $35.3 billion for Q4 2024.
- In Q4 2024, Interest & Investment Income rose 3533301692.76% year-over-year to $35.3 billion; the TTM figure through Dec 2024 stood at $35.3 billion (up 3533301692.76% YoY), while the FY2025 annual figure was $88058.7, down 59.03% from the prior year.
- Interest & Investment Income was $35.3 billion for Q4 2024 at Immuron, up from $999.32 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $35.3 billion in Q4 2024 to a low of -$77745.7 in Q2 2023.
- Historically, Interest & Investment Income has averaged $3.6 billion across 5 years, with a median of $1163.2 in 2023.
- The sharpest annual moves came in 2020 and 2023: Interest & Investment Income jumped 178613365704.8% in 2020, then plunged 398.25% in 2023.
- A 5-year view of Interest & Investment Income shows it stood at $4.6 billion in 2020, then plunged by 100.0% to $6737.5 in 2021, then plunged by 94.73% to $355.26 in 2022, then jumped by 181.29% to $999.32 in 2023, then surged by 3533301692.76% to $35.3 billion in 2024.
- The last three Interest & Investment Income figures came in at $35.3 billion (Q4 2024), $999.32 (Q4 2023), and $76247.4 (Q3 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -14.79 Mn |
| 10 | Immuron | 1.05 Bn | 1.05 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 35.31 Bn |
| Dec 31, 2023 | 999.32 |
| Sep 28, 2023 | 76,247.37 |
| Aug 30, 2023 | 1,163.23 |
| Jun 30, 2023 | -77,745.69 |
| Dec 31, 2022 | 355.26 |
| Aug 31, 2022 | 15,149.79 |
| Jun 30, 2022 | -15,603.91 |
| Dec 31, 2021 | 6,737.49 |
| Jun 30, 2021 | -7,087.59 |
| Dec 31, 2020 | 4.63 Bn |
| Dec 31, 2019 | 2.59 |
| Dec 31, 2018 | 39.00 |
| Dec 31, 2017 | 33.51 |